Capricor Therapeutics

BioTech/Drugs - Beverly Hills, CA, US

Capricor Therapeutics Employees
Firouz Mohsenian

Research Manager, Cell Biology

Contact Firouz Mohsenian

Terri Dalton

Contract Clinical Research Associate

Contact Terri Dalton

Veena Ramanna

Clinical Trial Manager

Contact Veena Ramanna

Contact All Capricor Therapeutics Employees
Capricor Therapeutics Details

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac cell therapy. CAP-1002 consists of cardiosphere-derived cells, or CDCs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system's activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. We are now focused on developing a precision-engineered exosome platform technology that can carry defined sets of effector molecules including nucleic acids which exert their effects through defined mechanisms of action. We have begun work on our expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases.

Capricor Therapeutics logo, Capricor Therapeutics contact details
Website: capricor.com
Employees: 50 - 99
HQ: 310-358-3200
Location: Beverly Hills, CA, US
Revenue: 5 - 10 Million
Cardiac Stem Cells Regeneration Cardiology Biotechnology Duchenne Muscular Distrophy Duchenne muscular dystrophy heart disease myocardial infarction exosomes B2B BioTech/Drugs Commercial Physical Research
Capricor Therapeutics Technologies
Email Providers

Outlook

Load Balancers

Ubuntu

Domain Name Services

Cloudflare DNS

Tag Management

Google Tag Manager

Hosting

CloudFlare Hosting

Other

Mobile Friendly

View All Technologies Used At Capricor Therapeutics

Contacting Capricor Therapeutics: Connect with Executives and Employees

Get in Touch with Capricor Therapeutics Executives and Employees

Connecting with Capricor Therapeutics's Executives and Workforce

Accessing Contact Information for Capricor Therapeutics Executives

Connecting with Capricor Therapeutics: Reach Out to Their Team

Discover How to Contact Capricor Therapeutics Executives and Staff

Looking to connect with Capricor Therapeutics executives or employees?

Seeking to Get in Touch with Capricor Therapeutics Executives or Staff?

Want to Reach Out to Capricor Therapeutics Executives or Team Members?

In Search of Contact Details for Capricor Therapeutics Professionals?

Connecting with Capricor Therapeutics: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z